All In Biotech

Drug Trial Radar · NCT05719558

A Study of ASP1002 in Adults for Treatment of Solid Tumors

A Phase 1 Study of ASP1002 in Participants With Metastatic or Locally Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

798

Planned (sponsor's estimate)

Start

Mar 13, 2023

Primary completion

Apr 30, 2030

Study completion May 31, 2030

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Feb 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). Claudin 4 protein, or CLDN4, is a protein found on tumors in different parts of the body. ASP1002 is thought to work by attaching to the CLDN4 protein in the tumor. This switches on the body's immune system to attack the tumor. Before ASP1002 can be used, researchers need to collect information about the safety of ASP1002 and how people with tumors tolerate it. In this study, ASP1002 will be given to humans for the first time. It will either be given by itself or together with other cancer treatments. These include standard chemotherapies (mFOLFOX6, FOLFIRI, TAS-102, pemetrexed, carboplatin, and docetaxel) and immunotherapies (bevacizumab, pembrolizumab, and ramucirumab). Immunotherapy is a treatment that works with the body's immune system to treat tumors. This is an early development study. These studies are mostly about safety, but also to find the most suitable dose. Other aims are to learn if ASP1002 shows signs of slowing down tumor growth, to learn how the body processes ASP1002, and to check if there are changes in the CLDN4 protein or the immune system after treatment. The main aims of the study are to check the safety of ASP1002 by itself and given with standard chemotherapies and immunotherapies in people with solid tumors and how well they tolerate the study treatments, and to find a suitable dose of ASP1002 by itself and in combination with standard chemotherapies and immunotherapies. People in this study will be adults with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). They will have been previously treated with available standard therapies, or they will have refused to receive those treatments. The key reasons people cannot take part are if they have symptoms of cancer in the brain or nervous system, have recently had other cancers that required treatment, or have diseases that affect the immune system or the heart. This study will be in 2 parts. In Part 1, different small groups of people will receive lower to higher doses of ASP1002 by itself and given with chemotherapies and immunotherapies. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP1002 to use in Part 2 of the study. In Part 2, other different small groups of people will receive doses of ASP1002, the chemotherapies and immunotherapies that worked the best in Part 1. In both parts of the study, ASP1002 will be given by itself and with standard chemotherapies and immunotherapies to people slowly through a tube into a vein. This is called an infusion. This will happen every 2 to 4 weeks, in treatment cycles. Treatment cycles may be 21 or 28 days long. People will continue to receive study treatment for up to 2 years or until their cancer gets worse, they can't tolerate the study treatment, they start other cancer treatments, or the doctor decides the person should stop receiving study treatment, or sadly, they pass away. They can also choose to stop taking the study treatment at any time without giving a reason. During the study, people will visit the clinic several times for a health check. This includes standard safety checks and reporting any medical problems. Every 2 months, the study doctors will check if each person's cancer has stayed the same, shrunk or disappeared over time. This will be done by scans (CT or MRI scans). Tumor samples will be taken during the study, and people will have the option of giving a tumor sample after study treatment has finished. People will have follow-up health checks for up to 1 year after their last dose of study treatment or until they start a different study treatment on a new study, whichever happens first.

Conditions

  • Advanced Solid Tumors

Interventions

  • ASP1002Drug

    Intravenous (IV) infusion. Dose interruptions, reductions, and treatment discontinuations will be implemented according to protocol-defined toxicity management criteria.

  • BevacizumabDrug

    IV infusion

  • OxaliplatinDrug

    IV infusion

  • LeucovorinDrug

    IV infusion

  • FluorouracilDrug

    IV infusion

  • IrinotecanDrug

    IV infusion

  • Trifluridine-TipiracilDrug

    Film-coated tablet

  • PembrolizumabDrug

    IV infusion

  • PemetrexedDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • RamucirumabDrug

    IV infusion

  • DocetaxelDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs) for ASP1002Time frame: Up to 24 months
  2. Number of participants with Adverse Events (AEs)Time frame: Up to 25 months
  3. Number of participants with Serious Adverse Events (SAEs)Time frame: Up to 27 months
  4. Number of participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: Up to 27 months
  5. Number of participants with vital sign abnormalities and/or adverse events (AEs)Time frame: Up to 27 months
  6. Number of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)Time frame: Up to 27 months
  7. Number of participants with physical exam abnormalities and/or Adverse Events (AEs)Time frame: Up to 24 months
  8. Number of participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status scoresTime frame: Up to 27 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Yale University Cancer Center

    New Haven, Connecticut · Recruiting

  • Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut

    Plainville, Connecticut · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • University of Iowa Hospitals

    Iowa City, Iowa · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • HealthPartners Cancer Research Center

    Saint Paul, Minnesota · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • University Hospitals of Cleveland

    Cleveland, Ohio · Recruiting

  • Prisma Health-Upstate Cancer Institute

    Greenville, South Carolina · Completed

  • SCRI Oncology Partners

    Nashville, Tennessee · Completed

  • University of Texas Southwestern

    Dallas, Texas · Completed

  • Mary Crowley Cancer Research Center

    Dallas, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

  • Swedish Cancer Institute

    Edmonds, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.